News

Drug Briefing: Olaparib

Views: 42     Author: Unibest Industrial     Publish Time: 2025-03-10      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button


Query Drug:Olaparib

Query Time:2025-03-10 13:13:19

*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.


About the Drug

Olaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.

Olaparib is often used if your cancer has a specific genetic marker, including BRAC1, BRCA2, HRR, and HER2-negative. Your doctor will test you for this gene.

Olaparib is a tablet that is usually taken twice daily, with or without food.

Lynparza was first FDA-approved in 2014 for advanced ovarian cancer.

Olaparib is FDA-approved to treat specific types of cancer.

Related Diseases

Extra Information on Drug and Diseases

Drug olaparib

RXCUI: 1597582

May Treat

  • Ovarian Neoplasms

Similar Drugs

[may_treat] Ovarian Neoplasms

Source MEDRT

[Physiological Effect] Decreased DNA Integrity

Source: MEDRT

[Physiological Effect] Decreased Reverse Transcription to DNA

Source: MEDRT

[Physiological Effect] Cellular Growth Phase Reduction

Source: MEDRT

[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors

Source DAILYMED

[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors

Source FDASPL

[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors

Source MEDRT

[Phamacological Category] Poly(ADP-Ribose) Polymerase Inhibitor

Source FDASPL

[Phamacological Category] Poly(ADP-Ribose) Polymerase Inhibitor

Source DAILYMED

Orange Book

[Last update] 2024-12-25

Labelers

Olaparib's Innovator is ASTRAZENECA PHARMACEUTICALS LP

Drug Products

The unique dosage forms from the innovator include:1. TABLET;ORAL;2. CAPSULE;ORAL.

Index Route Brand Name Labeler Approval Date Dosage
1 CAPSULE;ORAL LYNPARZA ASTRAZENECA PHARMACEUTICALS LP Dec 19, 2014 50MG
2 TABLET;ORAL LYNPARZA ASTRAZENECA PHARMACEUTICALS LP Aug 17, 2017 100MG
3 TABLET;ORAL LYNPARZA ASTRAZENECA PHARMACEUTICALS LP Aug 17, 2017 150MG

Drug Patents

This drug still has 12 effective patents.

Patent Number Submission Date Expiration Date Drug Substance Patent? Drug Product Patent?
8143241 Jan 15, 2015 Aug 12, 2027

8859562 Jan 15, 2015 Aug 4, 2031

8247416 Jan 15, 2015 Sep 24, 2028 Y
8475842 Sep 15, 2017 Dec 31, 2029
Y
7449464 Sep 15, 2017 Sep 8, 2027 Y Y
8071579 Jun 18, 2020 Aug 12, 2027

11633396 May 19, 2023 Oct 7, 2029
Y
11970530 May 28, 2024 Oct 25, 2041

11975001 Jun 3, 2024 Oct 7, 2029
Y
12048695 Aug 23, 2024 Oct 7, 2029
Y
12144810 Dec 10, 2024 Oct 7, 2029
Y
12178816 Jan 24, 2025 Oct 7, 2029
Y

Olaparib-Patent-Expiration

Related Company's Product Pipelines

The innovator ASTRAZENECA PHARMACEUTICALS LP's portolio contains products with the following 27 API(s): ISOSORBIDE DINITRATE, AMITRIPTYLINE HYDROCHLORIDE, QUETIAPINE FUMARATE, SELUMETINIB SULFATE, FELODIPINE, ZOLMITRIPTAN, TAMOXIFEN CITRATE, TOCAINIDE HYDROCHLORIDE, FULVESTRANT, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM, ATENOLOL, FORMOTEROL FUMARATE; GLYCOPYRROLATE, SODIUM ZIRCONIUM CYCLOSILICATE, TICAGRELOR, BUDESONIDE; FORMOTEROL FUMARATE, BUDESONIDE, OLAPARIB, ALBUTEROL SULFATE; BUDESONIDE, CAPIVASERTIB, OMEPRAZOLE, ROFLUMILAST, OMEPRAZOLE MAGNESIUM, ENALAPRIL MALEATE; FELODIPINE, OSIMERTINIB MESYLATE, OMEGA-3-CARBOXYLIC ACIDS, GEFITINIB

The above products are related to 105 diseases: Angina Pectoris, Esophageal Spasm, Diffuse, Coronary Disease, Cyanosis, Gastroesophageal Reflux, Poisoning, Heart Failure, Depressive Disorder, Pain, Bipolar Disorder, Schizophrenia, Depressive Disorder, Major, Psychotic Disorders, Autistic Disorder, Neurofibromatosis 1, Angina Pectoris, Variant, Hypertension, Migraine Disorders, Breast Neoplasms, Gynecomastia, Carcinoma, Ductal, Breast, Puberty, Precocious, Pancreatic Neoplasms, Breast Neoplasms, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Angina Pectoris, Atrial Fibrillation, Ventricular Fibrillation, Hypertension, Atrial Flutter, Tachycardia, Ventricular, Myocardial Infarction, Tachycardia, Supraventricular, Heart Failure, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Abnormalities, Drug-Induced, Respiratory Tract Diseases, Peptic Ulcer, Hyperhidrosis, Hyperkalemia, Myocardial Infarction, Stroke, Coronary Thrombosis, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Ovarian Neoplasms, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Breast Neoplasms, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Pulmonary Disease, Chronic Obstructive, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Arthritis, Rheumatoid, Hypertension, Malignant, Diabetic Nephropathies, Hypertrophy, Left Ventricular, Ventricular Dysfunction, Left, Edema, Bartter Syndrome, Heart Failure, Angina Pectoris, Variant, Hypertension, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung

ASTRAZENECA Pipeline